Emerging therapy
Epithalon
Epithalon is a synthetic four-amino-acid peptide derived from Russian work on pineal-gland extracts, sold online on the strength of telomere claims and decades-old longevity studies from the group that invented it. It is the clearest case on this site of a compound whose entire evidence base comes from its own developers.
Quick verdict
Cell-culture work — including a 2025 study — supports telomere lengthening in vitro. The human lifespan evidence is a small, non-randomised Soviet-era programme run by the peptide's developers, never independently replicated. No regulator anywhere has licensed it.
The assessment
Claim by claim
Each claim is graded on its own evidence. A grade for one claim says nothing about the others.
| Claim | What was measured | Evidence |
|---|---|---|
| Extends human lifespan | Lifespan | Early |
| Lengthens telomeres | Surrogate biomarker | Preclinical |
Extends human lifespan
Early human evidenceOutcome measured: Lifespan — Death from any cause was measured.
Uniquely among grey-market peptides, this claim cites human data: a 15-year follow-up of elderly Russians given the parent pineal preparation, reporting lower mortality in treated groups. Read the design before the result: participants were not randomised, the study was run by the peptide's developers, and no independent group has ever replicated it in half a century of opportunity.
Why this grade — the appraisal in full
One or a small number of small, short or preliminary human studies. Directionally interesting, not yet dependable.
- Strongest study design. Non-randomised trial.
- Human research volume. 1 human study, 0 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
- Study duration. Longest human study ran 780 weeks.
- Risk of bias. 1 human study is rated high risk of bias.
- Funding and conflicts. 1 of 1 human studies were funded by, or authored by, a party with a commercial interest in the result.
Limitations. Non-randomised allocation, developer-run with an obvious interest in the result, sample sizes and methods reported to a standard far below a modern trial, and zero independent replication. The rubric grades what exists; the factors panel shows why it should be read sceptically.
| Study | Design | Population | Finding |
|---|---|---|---|
| [1]Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly p…Bulletin of experimental biology and medicine · 2011 · PMID 22451889 | Non-randomised trialHuman | Size not recordedMixed population | Supports the claim15-year follow-up of elderly participants given pineal peptide preparations; lower mortality reported in treated groups. Non-randomised, developer-run, never independently replicated. |
Lengthens telomeres
Preclinical onlyOutcome measured: Surrogate biomarker — A laboratory marker measured as a stand-in for health. A change here does not by itself demonstrate a health benefit.
In human cell lines, recent work reports telomere lengthening via telomerase upregulation. That is a laboratory observation twice removed from a health benefit: no human trial has measured telomeres after epithalon, and telomere length itself is a contested marker of ageing.
Why this grade — the appraisal in full
Evidence comes from animals, cell cultures or modelling. No human trial has tested this claim. Animal lifespan results do not establish human benefit.
- Human evidence. No human study has tested this claim. Evidence comes from 0 animal studies and 1 laboratory study.
- Translation to humans. Results in animals frequently fail to reproduce in people. A lifespan effect in mice is not evidence of a lifespan effect in humans.
Limitations. Cell-culture only. Telomerase activation is also the mechanism many cancers depend on, which is a reason for caution as much as excitement.
| Study | Design | Population | Finding |
|---|---|---|---|
| [2]Epitalon increases telomere length in human cell lines through telomerase upregu…Biogerontology · 2025 · PMID 40908429 | Cell / in vitro studyLaboratory | Size not recorded | Supports the claimHuman cell lines; telomere lengthening via telomerase upregulation or ALT activity. |
Human evidence
1 study in people.
- [1]Non-randomised trial
Animal and laboratory evidence
Shown separately, and never used to support a human claim.
- Cell / in vitro study
Before anything else
Safety and interactions
No controlled human safety data meeting modern standards exist. As with all grey-market peptides, product identity and purity are unverified.
Regulatory and availability. Not licensed as a medicine in the UK or elsewhere; sold online outside medicines regulation as a 'research' compound.
The ledger
Grade history
22 August 2026
First published appraisal of this claim. Study links added: PMID 40908429.
22 August 2026
First published appraisal of this claim. Study links added: PMID 22451889.
Falsifiability
What would change our view
Any independent, randomised human trial. The originating group's own protocol tested in other hands would be the single most informative study possible here.
Check everything
Sources
Every citation links to its PubMed record. Bibliographic details are retrieved from PubMed, not written by us.
- [1]Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up Korkushko OV et al.. Bulletin of experimental biology and medicine. 2011. PMID 22451889 · doi:10.1007/s10517-011-1332-x
- [2]Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity Al-Dulaimi S et al.. Biogerontology. 2025. PMID 40908429 · doi:10.1007/s10522-025-10315-x